Hasan Mutlu1, Seyda Gündüz2, Abdullah Büyükçelik3, Ozcan Yıldız4, Mükremin Uysal5, Deniz Tural2, Hakan Bozcuk2, Hasan Şenol Coşkun2. 1. Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey. Electronic address: doktorhasanmutlu@gmail.com. 2. Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey. 3. Department of Internal Medicine, Acıbadem University School of Medicine, Istanbul, Turkey. 4. Department of Medical Oncology, Medipol University, Istanbul, Turkey. 5. Department of Medical Oncology, Kocatepe University School of Medicine, Afyon, Turkey.
Abstract
BACKGROUND: Targeted therapy has improved the survival of patients with metastatic RCC. In the present study, we evaluated whether there was an effect of cytoreductive surgery on prognosis of patients with metastatic RCC using antiangiogenic tyrosine kinase inhibitor (TKI) agents. PATIENTS AND METHODS: A total of 52 patients with metastatic RCC from Akdeniz University, Afyon Kocatepe University, and Medipol University participated in the study. All the patients had received targeted antiangiogenic therapy after interferon alfa-2b. According to previous CRN, the patients were divided into 2 groups as CRN (+) and CRN (-). RESULTS: The CRN (+) group was younger than the CRN (-) group (P < .001) and the hemoglobin levels were significantly higher in the CRN (+) group (P = .023). The median progression-free survival time from the date of starting TKIs were 8.5 and 3.0 months for the CRN (+) and CRN (-) groups, respectively (P = .104). The median overall survival was 15.1 and 5.4 months for the CRN (+) and CRN (-) groups, respectively (P = .034). CONCLUSION: We speculate that CRN is still an important part of treatment modalities in patients with metastatic RCC in modern era targeted therapy, which is currently the best systemic therapy. However, the indications of CRN might be limited to good-risk patients with metastatic RCC. Further randomized studies are warranted to clarify the necessity of CRN in patients with metastatic RCC.
BACKGROUND: Targeted therapy has improved the survival of patients with metastatic RCC. In the present study, we evaluated whether there was an effect of cytoreductive surgery on prognosis of patients with metastatic RCC using antiangiogenic tyrosine kinase inhibitor (TKI) agents. PATIENTS AND METHODS: A total of 52 patients with metastatic RCC from Akdeniz University, Afyon Kocatepe University, and Medipol University participated in the study. All the patients had received targeted antiangiogenic therapy after interferon alfa-2b. According to previous CRN, the patients were divided into 2 groups as CRN (+) and CRN (-). RESULTS: The CRN (+) group was younger than the CRN (-) group (P < .001) and the hemoglobin levels were significantly higher in the CRN (+) group (P = .023). The median progression-free survival time from the date of starting TKIs were 8.5 and 3.0 months for the CRN (+) and CRN (-) groups, respectively (P = .104). The median overall survival was 15.1 and 5.4 months for the CRN (+) and CRN (-) groups, respectively (P = .034). CONCLUSION: We speculate that CRN is still an important part of treatment modalities in patients with metastatic RCC in modern era targeted therapy, which is currently the best systemic therapy. However, the indications of CRN might be limited to good-risk patients with metastatic RCC. Further randomized studies are warranted to clarify the necessity of CRN in patients with metastatic RCC.
Authors: U Batra; P M Parikh; K Prabhash; H B Tongaonkar; P Chibber; D Dabkara; C Deshmukh; N Ghadyalpatil; S Hingmire; A Joshi; S K Raghunath; S Rajappa; R Rajendranath; S K Rawal; Manisha Singh; R Singh; S P Somashekhar; R Sood Journal: South Asian J Cancer Date: 2016 Oct-Dec
Authors: Stepan M Esagian; Ioannis A Ziogas; Dimitrios Kosmidis; Mohammad D Hossain; Nizar M Tannir; Pavlos Msaouel Journal: Cancers (Basel) Date: 2021-02-09 Impact factor: 6.639